Aingura is a big part of the puzzle. This statement from last quarter report:
Another reason we are optimistic of our future growth potential is the continued strength of the Aingura IIoT, S.G. collaboration. This quarter we received pass through funding from a grant in the amount of $70,400, as a result of our recent collaborative work with Aingura IIoT, S.G. We’re confident the resulting aforementioned use cases and marketing collateral, combined with our extensive prospects, several under NDA, will culminate in new customers and overall revenue growth
There is huge potential here. More from the report:
A counter balance to these headwinds are the achievements Year To Date in 2020: We completed a successful pilot program for our Fortune 500 Pharma customer, and also successfully completed a full year of data collection and analysis on our pilot structural health monitoring program for a New England state’s DOT. The underlying strengths of the Company are still in place: an experienced leadership team; contributions of a PhD level Machine Learning Algorithm engineer on our technology team; and strong execution on current contracts. Our continued focus on high potential growth markets (specifically Biotech, Pharma, and Medical Device Operations), have yielded numerous prospects for future growth. Furthermore, the strength of our target market, the Industrial Internet of Things (IIoT), continues: Market research shows the worldwide IIoT market in 2017 was $92 billion and is projected to be $227 billion by 2021 (25% CAGR).1
$227 billion market in 2021
When the next NDA goes to contract the rise will be quick, as there technology has been validated by the pilot programs. Why else would Aingura grant them money to continue if not for successful implementation?
IMO
News 
Market Data 
Discover 
